A dose-finding and discontinuation study of clomipramine in panic disorder
The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
Eighty-one panic disorder patients with or without agoraphobia were treated with flexible doses of clomipramine under single-blind conditions. Fifty-seven (70.3%) reached operational criteria for full remission in 16.2 ± 6.5 weeks, with a mean dose of 89.1 ± 8.2 mg/day. Fifty-four (81%) of them received a continuous post-remission maintenance treatment at full doses of clomipramine for 4–6 months. No patient relapsed during the clomipramine maintenance phase. Their medication was then tappered and discontinued with placebo substitution under double-blind conditions. Fifty-one (63%) patients were followed-up until relapse or recurrence for up to 3 years, with periodic assessments. Three different outcome groups were identified: the first (n = 19, 19; 37.2%) experienced an early/immediate relapse (5.2 ± 4.9 weeks after drug discontinuation); the second group (n= 22, 22; 43.1%) experienced recurrence after 42.9 ± 35 weeks following discontinuation; and the third group (n = 10, 10; 19.6%) remained assymptomatic and functionally well throughout the follow-up. Predictors of early relapse were: (1) higher baseline score in the Beck Depression Inventory; (2) higher global score on the phobic avoidance scale after the full remission criteria; and (3) the need for higher clomipramine doses to reach full remission. The need for long-term or intermittent maintenance for most patients is emphasized.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using the Cahill task we similarly found participants who received ATD had generally impaired recall after one week but with relative sparing of unpleasant compared with neutral scenes (Richell and Anderson, 2001).”
From Affective Cognition and its Disruption in Mood Disorders (2011) · cites this paper as Richell and Anderson, 2001
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 2×
“Instruments and ratings Following the clinical interview and a general physical examination, the following instruments were applied at intake: (1) Hamilton Depression Rating Scale, 21 items (HDRS; Hamilton, 1960); (2) Beck Depression Inventory (BDI; Beck et al.”
Method(1970) · Cited by 24,983
Diagnostic and Statistical Manual of Mental Disorders
&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,526
(1976) · Medical Entomology and Zoology · Cited by 8,899
Brief standard self-rating for phobic patients
Marks, I. M., & Mathews, A. M. (1979) · Behaviour Research and Therapy · doi:10.1016/0005-7967(79)90041-x · Cited by 1,801
Delineation of two drug-responsive anxiety syndromes
Klein, D. F. (1964) · Psychopharmacologia · doi:10.1007/bf02193476 · Cited by 898
Sheehan, D. V. (1984) · Medical Entomology and Zoology · Cited by 883
Treatment of Endogenous Anxiety With Phobic, Hysterical, and Hypochondriacal Symptoms
Sheehan, D. V. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140053006 · Cited by 729
Research works printed but not linked: 16
- Ballenger J C, 1992, J Clin Psychiatry, 53, 26
- Ballenger J C, 1993, Psychopharmacol Bull, 29, 477
- Ballenger J C, 1993, J Clin Psychiatry, 54, 15
- Dager S R, 1990, Psychopharmacol Bull, 26, 273
- Fyer A J, 1987, Am J Psychiatry, 143, 303
- Gentil V, 1986, Rev Assoc Med Brasil, 32, 101
- Gorman J M, 1990, J Clin Psychiatry, 51, 11
- Kupfer D J, 1991, J Clin Psychiatry, 52, 12
- Leonard B E, 1993, J Clin Psychiatry, 54, 3
- Maddock R J, 1993, J Clin Psychiatry, 54, 88
- Nagy L M, 1993, J Clin Psychopharmacol, 13, 16
- Noyes R Jr, 1989, J Clin Psychiatry, 50, 163
- Noyes R Jr, 1990, J Clin Psychiatry, 51, 24
- Pollack M H, 1990, J Clin Psychiatry, 51, 11
- Pollack M H, 1997, J Clin Psychiatry, 52, 57
- Rosenbaum JF, 1997, J Clin Psychiatry, 58, 3
Cited by
Affective Cognition and its Disruption in Mood Disorders
Elliott, R., Zahn, R., Deakin, J. F. W., & Anderson, I. M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.77 · Cited by 330
Antidepressant-induced jitteriness/anxiety syndrome: systematic review
Sinclair, L. I., Christmas, D. M., Hood, S. D., Potokar, J. P., Robertson, A., Isaac, A., Srivastava, S., Nutt, D. J., & Davies, S. J. C. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048371 · Cited by 181
“26 There is also evidence for jitteriness/anxiety syndrome with other tricyclics (clomipramine, 11,27,28 dothiepin (dosulepin) 26 and desipramine, 22 other SSRIs (sertraline (on dose titration rather than initiation) 29 and paroxetine) 30,31 and the 5-HT 1A agonist buspirone, 32 although less…”
Evidence-based pharmacotherapy of panic disorder: an update
Batelaan, N. M., Van Balkom, A. J. L. M., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000800 · Cited by 67
“For example, 37% of patients experienced a relapse within 10 wk of discontinuing clomipramine, and another 43% of patients within about 112 yr (Lotufo-Neto et al. 2001), over one third relapsed within the first year of imipramine discontinuation (Mavissakalian & Perel, 1999), and half of those who…”
Treatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57
WCA Recommendations for the Long-Term Treatment of Panic Disorder
Pollack, M. H., Allgulander, C., Bandelow, B., Cassano, G. B., Greist, J. H., Hollander, E., Nutt, D. J., Okasha, A., & Swinson, R. P. (2003) · CNS Spectrums · doi:10.1017/s109285290000691x · Cited by 55
Metadata
- Authors
- Lotufo-Neto, F., Bernik, M., Ramos, R. T., Andrade, L., Gorenstein, C., Cordás, T., Melo, M., & Gentil, V.
- Affiliations
- Institute of Psychiatry and Departament of Psychiatry, University of São Paulo Medical School, Brazil; Caixa Postal 3671 Departamento de Psiquiatria 01060—970 São Paulo Brazil;
- Universidade de São Paulo (BR)
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2001-01
- Volume
- 15
- Issue
- 1
- Pages
- 13-17
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1977727006
- Cited by
- 27
- References
- 58
- Citations by year
- 2020: 2 · 2013: 1 · 2012: 1
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- clomipramine, panic disorder, agoraphobia, dose-finding, drug discontinuation, recurrence prediction, maintenance therapy, tapering, predictors of relapse, phobic avoidance
- MeSH terms
- Adolescent, Adult, Antidepressive Agents, Tricyclic, Clomipramine, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Single-Blind Method, Panic Disorder
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A dose-finding and discontinuation study of clomipramine in panic disorder. https://app.cochat.ai/papers/10.1177/026988110101500103
- The paper
- Lotufo-Neto, F., Bernik, M., Ramos, R. T., Andrade, L., Gorenstein, C., Cordás, T., Melo, M., & Gentil, V. (2001). A dose-finding and discontinuation study of clomipramine in panic disorder. Journal of Psychopharmacology. https://doi.org/10.1177/026988110101500103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.